多靶点RTK抑制剂
| 英文名 | Dovitinib (TKI-258， CHIR-258) | CAS号 | 405169-16-6 |
| 试剂别名 |
4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;Dovitinib (TKI-258, CHIR-258);4-amino-5-fluoro-3- (6-(4-methylpiperazin-1-yl) -1H-benzo[d]imidazol-2-yl) quinolin-2(1H)-one;CHIR-258;Dovitinib;Dovitinib (CHIR-258,TKI-258);Dovitinib (TKI-258);Dovitinib-D8;TKI-258;4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one;4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;CHIR258;CHIR-258(Dovitinib);CHIR-258(Dovitinib,TKI258);TKI258;Unii-I35H55G906
|
分子式 | C21H21FN6O |
| 产品编号 | APEA2168 | 分子量 | 392.43 |
| MDL号 | MFCD10565680 |
| 产品名称： | 多靶点RTK抑制剂 |
| 英文名称： | Dovitinib (TKI-258， CHIR-258) |
| 英文别名： | 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;Dovitinib (TKI-258, CHIR-258);4-amino-5-fluoro-3- (6-(4-methylpiperazin-1-yl) -1H-benzo[d]imidazol-2-yl) quinolin-2(1H)-one;CHIR-258;Dovitinib;Dovitinib (CHIR-258,TKI-258);Dovitinib (TKI-258);Dovitinib-D8;TKI-258;4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one;4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one;CHIR258;CHIR-258(Dovitinib);CHIR-258(Dovitinib,TKI258);TKI258;Unii-I35H55G906 |
| 中文别名： | 多韦替尼 |
| CAS No.： | 405169-16-6 |
| 分子式： | C21H21FN6O |
| 分子量： | 392.43 |
| 危险品级别： | |
| HS符号： | |
| 危害声明： |
